Influenza Drug Market Report 2026

Influenza Drug Market Overview

• Influenza Drug market size has reached to $1.04 billion in 2025 • Expected to grow to $1.4 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: Rising Incidence Of Influenza Infections Fueling The Growth Of The Influenza Drug Market Due To Frequent Viral Mutations And Increased Vulnerability • Market Trend: Technological Advancements In Pediatric Influenza Care With Flavored Antivirals • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Influenza Drug Market?

An influenza drug is a medication used to prevent or treat influenza (the flu) by targeting the influenza virus. These drugs can work in different ways, such as inhibiting viral replication, blocking viral entry into host cells, or boosting the immune response against the virus. The main types of influenza drugs are influenza A, influenza B, and influenza C. Influenza A is a type of influenza virus that infects humans and various animals, causing seasonal flu epidemics and, occasionally, pandemics. The various rote of administering involved are oral, intranasal, intravenous, intramuscular, subcutaneous which are distributed through hospital pharmacies, retail pharmacies, online pharmacies by neuraminidase inhibitors, cap-dependent endonuclease inhibitors, fusion inhibitors, M2 ion channel inhibitors, host cell protease inhibitors, immunomodulatory agents, ribonucleic acid (RNA) polymerase inhibitors, hemagglutinin stem binders, cytokine inhibitors, host factor targeting mechanics. The end users involved are hospitals and clinics, pharmacies, vaccination centers, research institutions, government health agencies, long-term care facilities, community health centers, and corporate health programs.

What Is The Influenza Drug Market Growth Forecast?

The influenza drug market size is expected to see strong growth in the next few years. It will grow to $1.4 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to launch of next-generation antiviral therapies, expansion of vaccination campaigns, adoption of digital health monitoring tools, increasing government initiatives for flu prevention, growth in research on host-targeted therapies. Major trends in the forecast period include increasing adoption of rapid diagnostic testing for influenza, rising demand for broad-spectrum antiviral drugs, expansion of vaccination programs and preventive care initiatives, integration of telemedicine and remote patient monitoring, growth in personalized and targeted influenza therapies.

What Is The Driver Of The Influenza Drug Market?

The rising incidence of influenza infections is expected to propel the growth of the influenza drug market going forward. Influenza infections are contagious respiratory illnesses caused by influenza viruses, leading to symptoms such as fever, cough, sore throat, and body aches. The rising incidence of influenza infections is driven by frequent viral mutations that weaken vaccine effectiveness and increase population vulnerability to outbreaks. Influenza drugs prevent the rising incidence of influenza infections by providing effective treatment options that help reduce disease severity and control widespread transmission. For instance, in September 2023, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency of the United States, in the 2022–2023 season, preliminary in-season estimates show that influenza virus infections in the United States caused 31 million symptomatic illnesses, 14 million medical visits, 360,000 hospitalizations, and 21,000 deaths. Therefore, the rising incidence of influenza infections is driving the growth of the influenza drug industry.

Key Players In The Global Influenza Drug Market

Major companies operating in the influenza drug market are F. Hoffmann-La Roche Ltd., Pfizer Inc., AstraZeneca PLC, GlaxoSmithKline plc, Daiichi Sankyo Co. Ltd., Shionogi & Co. Ltd., Green Cross Corp, Emergent BioSolutions Inc., BioCryst Pharmaceuticals Inc., SAB Biotherapeutics Inc., Viriom Inc., Cocrystal Pharma Inc.

Global Influenza Drug Market Trends and Insights

Major companies operating in the influenza drug market are focusing on technological advancements, such as drug formulation, to enhance treatment effectiveness, patient compliance, and overall therapeutic outcomes. Drug formulation typically involves combining inert materials and excipients with active pharmaceutical ingredients (APIs) to produce viable drug products with desired properties. For instance, in August 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based company that focuses on pharmaceuticals and diagnostics, launched Baloxavir Marboxil for Suspension, a strawberry-flavored, single-dose oral antiviral designed for children, enabling parents to administer accurate weight-based dosing, enhancing ease of administration and compliance. This innovation introduces a precise home-based medication delivery alternative aligned with the context of prescription delivery service by allowing carers to manage pediatric influenza treatment conveniently at home, following a prescription. Strengths include novel mechanism specificity and improved adherence; however, resistance may emerge over time, especially among pediatric patients.

What Are Latest Mergers And Acquisitions In The Influenza Drug Market?

In July 2024, GlaxoSmithKline plc, a Netherlands-based company that focused on discovering, developing, and delivering innovative medicines and vaccines, partnered with CureVac N.V. With this partnership, GSK aimed to strengthen its mRNA vaccine platform, accelerate development of COVID-19 and influenza vaccine candidates, and enhance its infectious-disease pipeline. CureVac N.V. is a Germany-based company that specializes in the development of influenza drugs.

What Defines the Influenza Drug Market?

The influenza drug market consists of sales of oseltamivir phosphate, rimantadine, zanamivir, baloxavir marboxil and favipiravir (avigan or fabiflu). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Influenza Drug Market Report 2026?

The influenza drug market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the influenza drug industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.